Under Investigation: Preventive care on the horizon
Not all patients who share a certain organ involvement can be treated with the same medicine at the same dose. In this piece, Foundation Medical Director Dr. Joan Merrill argues that improved classification of lupus can lead to better treatment.
Off-label drugs for the treatment of lupus symptoms represents the standard of care for people with lupus, but current regulations make it difficult for doctors and manufacturers to communicate. Read Sandra C. Raymond's remarks now.
Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
George C. Tsokos, M.D., Chief of the Rheumatology Division at Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School, has been selected as the 2015 recipient of the Lupus Insight Prize.
LFA-REAL aims to improve health and quality of life for people with lupus.
People with lupus need and deserve a full arsenal of treatments. With many new and innovative drugs for lupus in the drug pipeline, these highly anticipated treatments will mean nothing if people with lupus cannot afford them.